00000nam 2200000zi 4500 9.937672 CaOODSP 20240724151156 m o d f cr mn||||||||| 240502t20242024oncd ob f000 0 eng d 9780660717234 CaOODSP eng rda CaOODSP n-cn--- HP40-286/2024E-PDF Use of measles-mumps-rubella (MMR) vaccine for the management of mumps outbreaks in Canada. [Revised 2024 edition]. Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, 2024. ©2024 1 online resource (54 pages) : graphs text txt rdacontent computer c rdamedia online resource cr rdacarrier Cover title. "Revised publication: 2024." Issued also in French under title: Utilisation du vaccin contre la rougeole, la rubéole et les oreillons (RRO) pour la prise en charge des éclosions d'oreillons au Canada. At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). "Notice to reader: The errors in the references have been corrected." Includes bibliographical references (pages 33-39). "This Statement provides an evidence summary and recommendations on the topic of additional dose(s) of MMR vaccine provided in mumps outbreak settings, including the off-label administration of a third dose of MMR vaccine (MMR3) in individuals who were previously vaccinated with two valid doses, for consideration by public health programs"--Page 4. Mumps Vaccination Canada. Public Health Agency of Canada, issuing body. Canada. National Advisory Committee on Immunization, issuing body. Utilisation du vaccin contre la rougeole, la rubéole et les oreillons (RRO) pour la prise en charge des éclosions d'oreillons au Canada. (CaOODSP)9.937673 Use of measles-mumps-rubella (MMR) vaccine for the management of mumps outbreaks in Canada. [July 2021 edition] (CaOODSP)9.898655 PDF 1,009 KB https://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-286-2024-eng.pdf HTML N/A https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/use-measles-mumps-rubella-vaccine-management-outbreaks-canada.html 240116